trending Market Intelligence /marketintelligence/en/news-insights/trending/71TFJet5x3ll5As3yGqa7w2 content esgSubNav
In This List

Kyowa Hakko sets up new company to advance generic medicine

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Kyowa Hakko sets up new company to advance generic medicine

Japan-based Kyowa Hakko Kirin Co. Ltd. established Kyowa Kirin Frontier Co. Ltd. with ¥100 million in capital.

The new company will work on getting manufacturing and marketing approval for an authorized generic of NESP, Kyowa Hakko Kirin's key product to help boost red blood cell production in kidney disease patients with anemia.

Kyowa Kirin Frontier will be headed by Wataru Murata as CEO and executive director of the board.

As of Jan. 31, US$1 was equivalent to ¥112.39.